Second cancers in radically treated Norwegian prostate cancer patients

References

• Wood ME, Vogel V, Ng A. Second malignant neoplasms: assessment and strategies for risk reduction. JCO. 2012;30:3734–3745.
   PubMed Web of Science ®Google Scholar
• Travis LB, Demark Wahnefried W, Allan JM, et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013;10:289–301.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023–1075.
   PubMed Web of Science ®Google Scholar
• The Cancer Registry of Norway; [cited 2018 Sept 13]. Available from: https://www.kreftregisteret.no/en
   Google Scholar
• Ron E. Ionizing radiation and cancer risk: evidence from epidemiology. Radiation Res. 1998;150:S30–S41.
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Curtis RE, Hall EJ, et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88:398–406.
   PubMed Web of Science ®Google Scholar
• Margel D, Baniel J, Wasserberg N, et al. Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer. Ann Surg. 2011;254:947–950.
   PubMed Web of Science ®Google Scholar
• Murray L, Henry A, Hoskin P, et al. Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique. Radiotherapy Oncol. 2014;110:213–228.
   PubMed Web of Science ®Google Scholar
• Wallis CJ, Mahar AL, Choo R, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ 2016;352:i851.
   PubMed Web of Science ®Google Scholar
• Moon K, Stukenborg GJ, Keim J, et al. Cancer incidence after localized therapy for prostate cancer. Cancer 2006;107:991–998.
   PubMed Web of Science ®Google Scholar
• Baxter NN, Tepper JE, Durham SB, et al. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology 2005;128:819–824.
   PubMed Web of Science ®Google Scholar
• Berrington de Gonzalez A, Curtis RE, Kry SF, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12:353–360.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Pei X, Teslova T, et al. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int. 2012;110:1696–1701.
   PubMed Web of Science ®Google Scholar
• Kendal WS, Eapen L, Macrae R, et al. Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer. Int J Radiat Oncol Biol Phys. 2006;65:661–668.
   PubMed Web of Science ®Google Scholar
• Hegemann NS, Schlesinger-Raab A, Ganswindt U, et al. Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis. Radiat Oncol. 2017;12:2.
   PubMed Web of Science ®Google Scholar
• Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45:1218–1231.
   PubMed Web of Science ®Google Scholar
• Lovdata. Forskrift om innsamling og behandling av helseopplysninger i Kreftregisteret Lovdata; 2002 [cited 2018 May 4]. Available from: https://lovdata.no/dokument/SF/forskrift/2001-12-21-1477
   Google Scholar
• Aalen OO, Johansen S. An empirical transition matrix for non-homogeneous markov chains based on censored observations. Scand J Stat. 1978;5:141–150.
   Web of Science ®Google Scholar
• Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43–46.
   PubMedGoogle Scholar
• Braisch U, Meyer M, Radespiel-Tröger M. Risk of subsequent primary cancer among prostate cancer patients in Bavaria, Germany. Eur J Cancer Prevention. 2012;21:552–559.
   PubMed Web of Science ®Google Scholar
• Davis EJ, Beebe-Dimmer JL, Yee CL, et al. Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study. Cancer 2014;120:2735–2741.
   PubMed Web of Science ®Google Scholar
• Bhojani N, Capitanio U, Suardi N, et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol. 2010;76:342–348.
   PubMed Web of Science ®Google Scholar
• Botteri E, Iodice S, Bagnardi V, et al. Smoking and colorectal cancer: a meta-analysis. JAMA 2008;300:2765–2778.
   PubMed Web of Science ®Google Scholar
• Leppert JT, Shvarts O, Kawaoka K, et al. Prevention of bladder cancer: a review. Eur Urol. 2006;49:226–234.
   PubMed Web of Science ®Google Scholar
• Boorjian S, Cowan JE, Konety BR, et al. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2007;177:883–887; discussion 887–888.
   PubMed Web of Science ®Google Scholar
• Van Hemelrijck M, Feller A, Garmo H, et al. Incidence of second malignancies for prostate cancer. PLoS One. 2014;9:e102596.
   PubMed Web of Science ®Google Scholar
• Neugut AI, Ahsan H, Robinson E, et al. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer 1997;79:1600–1604.
   PubMed Web of Science ®Google Scholar
• Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol. 2014;15:223–231.
   PubMed Web of Science ®Google Scholar
• Wiltink LM, Nout RA, Fiocco M, et al. No increased risk of second cancer after radiotherapy in patients treated for rectal or endometrial cancer in the randomized TME, PORTEC-1, and PORTEC-2 trials. J Clin Oncol. 2015;33:1640–1646.
   PubMed Web of Science ®Google Scholar
• Warschkow R, Guller U, Cerny T, et al. Secondary malignancies after rectal cancer resection with and without radiation therapy: a propensity-adjusted, population-based SEER analysis. Radiotherapy Oncol. 2017;123:139–146.
   PubMed Web of Science ®Google Scholar
• Statistics Norway. Statistisk sentralbyrå. 2018; [cited 2018 September 13]. Available from: https://www.ssb.no/en
   Google Scholar
• Riad S, Biau D, Holt GE, et al. The clinical and functional outcome for patients with radiation-induced soft tissue sarcoma. Cancer 2012;118:2682–2692.
   PubMed Web of Science ®Google Scholar
• Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J. Urol. 2008;180:2005–2009; discussion 2009–2010.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab M, Reis IM, Hamilton K. Second primary cancer after radiotherapy for prostate cancer—a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol, Biol, Phys. 2008;72:58–68.
   PubMed Web of Science ®Google Scholar
• Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av prostatakreft [Internet]. 2015 [cited 2017 May 30]. Available from: http://www.helsebiblioteket.no/retningslinjer/prostatakreft
   Google Scholar
• Murray LJ, Thompson CM, Lilley J, et al. Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy. Phys Med Biol. 2015;60:1237–1257.
   PubMed Web of Science ®Google Scholar
• Stokkevag CH, Engeseth GM, Hysing LB, et al. Risk of radiation-induced secondary rectal and bladder cancer following radiotherapy of prostate cancer. Acta Oncol. 2015;54:1317–1325.
   PubMed Web of Science ®Google Scholar